Phase 2 Thrombocytopenia Clinical Trials
62 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 62 trials
Recruiting
Phase 2Phase 3
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
Immune Thrombocytopenic PurpuraITPIdiopathic Thrombocytopenic Purpura+4 more
argenx24 enrolled10 locationsNCT07194850
Recruiting
Phase 2
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Primary Immune Thrombocytopenia (ITP)Primary Evans Syndrome (ES)
Novartis Pharmaceuticals164 enrolled2 locationsNCT07421167
Recruiting
Phase 2
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
Warm Autoimmune Hemolytic AnemiaPrimary immune thrombocytopenia
Novartis Pharmaceuticals60 enrolled22 locationsNCT07039422
Recruiting
Phase 2
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
Severe Aplastic AnemiaAcquired Amegakaryocytic ThrombocytopeniaAcquired Pure Red Cell Aplasia+1 more
Masonic Cancer Center, University of Minnesota60 enrolled1 locationNCT06412497
Recruiting
Phase 2
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Immune Thrombocytopenia
Incyte Corporation56 enrolled40 locationsNCT07104565
Recruiting
Phase 2
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
Immune Thrombocytopenia (ITP)
Nuvig Therapeutics, Inc.30 enrolled1 locationNCT07095127
Recruiting
Phase 1Phase 2
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Immune Thrombocytopenia (ITP)
Eli Lilly and Company58 enrolled45 locationsNCT06721013
Recruiting
Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
Primary immune thrombocytopenia
Pfizer91 enrolled31 locationsNCT05070845
Recruiting
Phase 2
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
Breast CancerGynecologic CancersOvarian Cancer+7 more
Peking University People's Hospital220 enrolled1 locationNCT07586826
Recruiting
Phase 2
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
Colorectal, CancerPancreatic CancerGastrointestinal Neoplasms+2 more
Peking University People's Hospital220 enrolled1 locationNCT07586813
Recruiting
Phase 2
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
Solid TumorsAdolescentChemotherapy Induced Thrombocytopenia+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences50 enrolled1 locationNCT07043894
Recruiting
Phase 2
Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)
ThrombocytopeniaCancer Treatment-induced Thrombocytopenia
Zhejiang Cancer Hospital25 enrolled1 locationNCT07441720
Recruiting
Phase 1Phase 2
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
ITPImmune Thrombocytopenia (ITP)Monoclonal+2 more
Climb Bio, Inc.24 enrolled20 locationsNCT07043946
Recruiting
Phase 2
Luspatercept for Clonal Cytopenias of Uncertain Significance
ThrombocytopeniaNeutropeniaAnemia+2 more
Weill Medical College of Cornell University50 enrolled1 locationNCT06788691
Recruiting
Phase 2
Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors
Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors
Changhai Hospital40 enrolled1 locationNCT07492693
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
Thrombocytopenia Associated With Chronic Liver Disease
Chongqing Peg-Bio Biopharm Co., Ltd.54 enrolled8 locationsNCT07446491
Recruiting
Phase 2
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
MyelofibrosisModerate ThrombocytopeniaMild Thrombocytopenia
Karyopharm Therapeutics Inc58 enrolled70 locationsNCT05980806
Recruiting
Phase 2
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China160 enrolled1 locationNCT07297563
Recruiting
Phase 2
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China160 enrolled1 locationNCT07234019
Recruiting
Phase 2
The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia
Relapsed/Refractory Immune Thrombocytopenia
Seoul National University Hospital29 enrolled4 locationsNCT05599880